High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study
High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study
复制标题
DOI：
10.3324/haematol.2010.034991
复制
发表时间：
2011-08-01
期刊：
影响因子：
--
通讯作者：
Hansen, John-Bjarne
中科院分区：
文献类型：
--
作者：
Hald, Erin M.;Braekkan, Sigrid K.;Hansen, John-Bjarne
背景高敏C反应蛋白与动脉性心血管疾病的风险相关，但其在静脉血栓栓塞性疾病中的作用的研究结果相互矛盾。我们的研究的目的是探讨高敏C反应蛋白水平和未来静脉血栓栓塞症的风险之间的关联在一个前瞻性队列招募从一般population.Design和MethodsHigh-sensitivity C反应蛋白测定血清样本从6,426名男性和女性，年龄25-84岁，招募的特罗姆瑟研究在1994-1995年期间。在中位数为12.5年的随访期间登记了静脉血栓栓塞事件（n=209）。考克斯比例风险回归模型用于估计总静脉血栓栓塞的年龄、性别和多变量校正的风险比（95%置信区间），结果高敏C反应蛋白水平每增加1个标准差，静脉血栓栓塞的风险不会增加（风险比1.08; 95%置信区间0.95-1.23）或高敏C反应蛋白四分位数（P趋势0.6）。进一步调整体重指数、吸烟和糖尿病并没有改变风险估计。此外，高敏C-反应蛋白与静脉血栓栓塞在任何性别特异性分析或单独分析的挑起和无端的静脉血栓栓塞events.ConclusionsIn这项前瞻性研究，血清中的高敏C-反应蛋白水平与静脉血栓栓塞的未来发展无关。我们的研究结果并不表明C反应蛋白在静脉血栓栓塞症的发病机制中发挥因果作用。
BackgroundHigh-sensitivity C-reactive protein is associated with risk of arterial cardiovascular disease but conflicting results have been reported on its role in venous thromboembolic disease. The objective of our study was to investigate the association between high-sensitivity C-reactive protein levels and risk of future venous thromboembolism in a prospective cohort recruited from a general population.Design and MethodsHigh-sensitivity C-reactive protein was measured in serum samples from 6,426 men and women, aged 25-84 years, recruited from the Tromso Study in the period 1994-1995. Incident venous thromboembolism events (n=209) were registered during a median of 12.5 years of follow up. Cox's proportional hazards regression models were used to estimate age- and gender- and multivariable-adjusted hazard ratios with 95% confidence intervals for total venous thromboembolism, and for provoked and unprovoked venous thromboembolism by increasing levels of high-sensitivity C-reactive protein.ResultsThere was no increased risk of venous thromboembolism per 1 standard deviation increase in high-sensitivity C-reactive protein (hazard ratio 1.08; 95% confidence interval 0.95-1.23) or across quartiles of high-sensitivity C-reactive protein (P for trend 0.6) in analyses adjusted for age and gender. Further adjustment for body mass index, smoking and diabetes did not alter the risk estimates. Moreover, high-sensitivity C-reactive protein was not associated with venous thromboembolism in either gender specific analysis or in separate analyses of provoked and unprovoked venous thromboembolism events.ConclusionsIn this prospective study, serum levels of high-sensitivity C-reactive protein were not associated with future development of venous thromboembolism. Our findings do not suggest a causal role for C-reactive protein in the pathogenesis of venous thromboembolism.